Neuroimmunology Drug Development
Join us and leading neuroimmunology speakers, including Roche, Vigil Neuroscience, Merck, Lundbeck, Pipeline Therapeutics, and BMS, across 3 jam-packed conference days spanning discovery, preclinical, and translational development. To explore "Harnessing State-of-the-Art Microglial iPSCs, In Vivo Models & Neuroinflammatory Biomarkers to Accelerate Neurodegenerative Drugs into the Clinic".
Join us and leading neuroimmunology speakers, including Roche, Vigil Neuroscience, Merck, Lundbeck, Pipeline Therapeutics, and BMS, across 3 jam-packed conference days spanning discovery, preclinical, and translational development. To explore "Harnessing State-of-the-Art Microglial iPSCs, In Vivo Models & Neuroinflammatory Biomarkers to Accelerate Neurodegenerative Drugs into the Clinic".
We are sponsors at this event!
Come and visit our team at our booth and meet our team to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, and high-content imaging applications.
We will be hosting a talk on ioMicroglia: Revolutionizing Neurodegenerative Disease Drug Development:
- See characterisation and functional data on precision reprogrammed hiPSC-derived ioMicroglia that show phagocytosis and cytokine secretion within days, enabling consistent, rapid and physiologically relevant results
- Discover how ioDisease models for late-onset Alzheimer's allow precise identification of disease-related effects when compared with genetically matched ioWild Type Cells
- Gain insights into CRISPR-Ready ioMicroglia, offering scalable and consistent CRISPR screens for drug target discovery in physiologically relevant human cell types.